Cours Synaptogenix, Inc. Other OTC
Actions
SNPX
US87167T1025
Recherche biotechnologique et médicale
CA 2022 | - | CA 2023 | - | Capitalisation | 5,54 M 5,05 M |
---|---|---|---|---|---|
Résultat net 2022 | -5 M -4,55 M | Résultat net 2023 | -6 M -5,47 M | VE / CA 2022 | - |
Trésorerie nette 2022 | 37,48 M 34,14 M | Trésorerie nette 2023 | 30,1 M 27,42 M | VE / CA 2023 | - |
PER 2022 |
-1,42
x | PER 2023 |
-0,23
x | Employés | - |
Rendement 2022 * |
-
| Rendement 2023 |
-
| Flottant | 97,86% |
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Alan Tuchman
CEO | Chief Executive Officer | 77 | 01/01/18 |
Daniel Alkon
PSD | President | 81 | 07/12/20 |
Robert Weinstein
DFI | Director of Finance/CFO | 64 | 01/10/13 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Alan Tuchman
CEO | Chief Executive Officer | 77 | 01/01/18 |
Bruce Bernstein
BRD | Director/Board Member | 60 | 14/11/16 |
Joshua Silverman
CHM | Chairman | 53 | 04/08/16 |
Varia. 1 janv. | Capi. | |
---|---|---|
+49,71% | 63,85 Md | |
-2,60% | 41,83 Md | |
+40,01% | 40,47 Md | |
-10,22% | 27,17 Md | |
+13,59% | 26,52 Md | |
-20,92% | 18,69 Md | |
+3,06% | 12,73 Md | |
+22,14% | 12,11 Md | |
+27,34% | 12,07 Md |